Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

SBS Ventures

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 1
Average round size
info
The average size of a deal this fund participated in
$20M
Portfolio companies 1
Lead investments 0
Key employees 1

Areas of investment

  • Medical
  • Internet
  • Life Science
  • Health Care
Summary

The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is generally included in less than 2 deals every year. The important activity for fund was in 2000.

Among the various public portfolio startups of the fund, we may underline ELabsEurope We can highlight the next thriving fund investment areas, such as Life Science, Medical.

The standard case for the fund is to invest in rounds with 4 partakers. The meaningful sponsors for the fund in investment in the same round are Sapphire Ventures, Inventures, Atlas Venture.

The overall number of key employees were 1.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of SBS Ventures:
There are no funds here. If we find new data, we will add it here.
Typical Co-investors
SBS Ventures is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after SBS Ventures:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Aeternity Liechtenstein, Oberland, Vaduz
Alive Ideas France, Ile-de-France, Paris
AWTG -
Beijing Ronghui Tongda Touzi Quanli Youxian Gongsi Beijing, China, Haidian
Burda International Bayern, Germany, Munich
Calyon Financial Chicago, Illinois, United States
Chengdu Hi-tech Investment Group -
Dauk/Wagner Investments Connecticut, Ridgefield, United States
HealthCare Biotech China, Hubei, Wuhan
Huaneng Capital Beijing, Beijing, China
Maple Capital Advisors -
MAR ventures Brazil, São Paulo, Sao Paulo
Nakashimato Chiyoda, Japan
Qujingshi Qilinqu Gongye Yuanqu Kaifa Touzi China, Qujing, Yunnan
ROCA Partners Beverly Hills, California, United States
San Diego Venture Partners -
TDM Growth Partners Australia, New South Wales, Sydney
Wenzhou Dongchuang Xinhui -
Xinbaijia Wenhua Chuanbo China, Shanghai

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

ELabsEurope

Health Care
Internet
Life Science
Medical
$20M23 Oct 2000 Munich, Bavaria, Germany

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent SBS Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: